Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

BACKGROUND: Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Beelen, Karin, Opdam, Mark, Severson, Tesa, Koornstra, Rutger, Vincent, Andrew, Wesseling, Jelle, Sanders, Joyce, Vermorken, Jan, van Diest, Paul, Linn, Sabine
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6057037/
https://ncbi.nlm.nih.gov/pubmed/30041599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4516-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky